Browse Results

  • Division: : Cancer Center


There are 199 clinical trial(s) matching your criteria.

Back

Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia

Investigator: Ronan Swords

Institutional Protocol #: 20151147

National Clinical Trials Identifier: NCT02610777

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 7/11/2016

1138131 A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinase A, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post- Polycythemic Myelofibrosis)

Investigator: Ronan Swords

Institutional Protocol #: 20151074

National Clinical Trials Identifier: NCT02530619

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I

Enrolling Since: 6/24/2016

“A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum Based Therapy”.

Investigator: Rakesh Singal

Institutional Protocol #: 20150428

National Clinical Trials Identifier: NCT02426125

Division: Cancer Center

Therapeutic Area: Prostate, Bladder, and Kidney Cancers

Phase: Phase III

Enrolling Since: 5/19/2016

A 1-Year Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Umbilical Cord Blood Cells Expanded Ex Vivo with Mesenchymal Precursor Cells for Hematopoietic Recovery in Patients With Hematologic Malignancies After Myeloablative Conditioning

Investigator: Denise Pereira

Institutional Protocol #: 20140789

National Clinical Trials Identifier: NCT01854567

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 9/10/2015

Thyroid cancer and MMPs

Investigator: Sharon Elliot

Institutional Protocol #: 20057541

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Thyroid and Other Endocrine Cancers

Phase: N/A

Enrolling Since: 6/24/2008

Back